Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen Inc, Astrazeneca AbfiledCriticalPozen Inc
Priority to CU20110050ApriorityCriticalpatent/CU20110050A7/en
Publication of CU20110050A7publicationCriticalpatent/CU20110050A7/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente divulgación se refiere al uso de naproxeno, o una sal farmacéuticamente aceptable de este, y esomeprazol, o una sal farmacéuticamente aceptable de este, en la fabricación de una composición farmacéutica en forma de dosis unitaria, donde dicho esomeprazol, o una sal farmacéuticamente aceptable de este, se libera de dicha forma de dosis unitaria a un pH especificado, donde una forma de dosis unitaria es para su administración como una dosis matutina y una segunda forma de dosis unitaria es para su administración como una dosis vespertina para obtener un perfil farmacocinético especificado.The present disclosure relates to the use of naproxen, or a pharmaceutically acceptable salt thereof, and esomeprazole, or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition in unit dose form, wherein said esomeprazole, or a pharmaceutically acceptable salt. acceptable from this, it is released from said unit dose form at a specified pH, where a unit dose form is for administration as a morning dose and a second unit dose form is for administration as an evening dose to obtain a profile Specified pharmacokinetic.
CU20110050A2011-03-092011-03-09
METHOD OF ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION TO A PATIENT WHO NEEDS IT
CU20110050A7
(en)
compound of the formula bl (d) x, or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound, unit dosage form or unit dose composition, composition for treating a cancer in a patient, and method for treating a cancer in a patient
compound, pharmaceutical composition, use of the compound or a pharmaceutically acceptable salt thereof, and method of treating an hcv infected patient
DERIVATIVES OF ESTRA- 1,3,5 (10), 16- TETRAEN- 3- CARBOXIMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
DIMALEATE OF 9- [4- (3-CHLORINE-2-FLUORO-PHENYLAMINE) -7-METOXI-QUINAZOLIN-6-ILOXI] -1,4-DIAZA-ESPIRO [5.5] UNDECAN-5-ONA, ITS USE AS A MEDICINAL PRODUCT AND HIS PREPARATION.
compound or salt thereof, pharmaceutical composition, methods for producing antiprogestational effect in a patient and for treating progesterone dependent condition and uses of the compound or pharmaceutically acceptable salt thereof and composition